Literature DB >> 21846833

Dosing voriconazole in an obese patient.

Natalie J Dickmeyer, Patrick J Kiel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21846833     DOI： 10.1093/cid/cir511

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  3 in total

1.  Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.

Authors:  Brad Moriyama; Paul F Jarosinski; William D Figg; Stacey A Henning; Robert L Danner; Scott R Penzak; Alan S Wayne; Thomas J Walsh
Journal:  Pharmacotherapy       Date:  2013-02-11       Impact factor: 4.705

2.  Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.

Authors:  Ping Liu; Diane R Mould
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

3.  Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.

Authors:  Helen Y Chu; Rupali Jain; Hu Xie; Paul Pottinger; David N Fredricks
Journal:  BMC Infect Dis       Date:  2013-02-26       Impact factor: 3.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.